^
    Back
    Association details:
    Biomarker:PD-L1 overexpression
    Cancer:Thymoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Gan To Kagaku Ryoho
    Title:

    A Case of Recurrent Thymoma Treated with Pembrolizumab as the Fifth-Line Chemotherapy

    Published date:
    10/01/2020
    Excerpt:
    Pembrolizumab was administered as fifth-line chemotherapy every 4 weeks at a dosage of 200 mg. After 3 courses, the lesions had remarkably decreased. This suggests that pembrolizumab for thymoma with high PD-L1 expression is efficacious.